Eli Lilly falls after late-stage data for oral weight-loss drug

Shares of drugmaker Eli Lilly LLY.N fall 11.6% to $660.53 premarket

Co reports late-stage data from its oral weight loss drug, orforglipron

Orforglipron helped overweight or obese patients lose 12.4% of their body weight on average after 72 weeks in a late-stage study -LLY

Says just over 10% of the high-dose patients dropped out of the trial due to adverse side effects

Up to last close, stock down 3.3% YTD